To investigate the effect of the prognostic nutritional index on treatment response and survival in patients with metastatic renal cell cancer.

We retrospectively analyzed the treatment modalities; the demographic, clinical and pathological features of 396 patients with RCC and prognostic nutritional index. Based on the median value, patients were grouped as having low and high prognostic nutritional index values. Kaplan-Meier method was used for survival analysis, and Cox-regression analysis was used for multivariate analysis.

The median overall survival was 39 months (95% CI 26.1-51.8), 28 months (95% CI 17.9-38) and 7 months (95% CI 4.7-9.2) in patients with favorable, intermediate and poor International Metastatic Renal Cell Carcinoma Database Consortium risk group, respectively. The difference between the groups was statistically significant (p < 0001). Overall survival was 11 months (95% CI 7.5-14.5) in the low-prognostic nutritional index (prognostic nutritional index ≤38.5) group, and 41 months (95% CI 30.5-51.4) in the high prognostic nutritional index (prognostic nutritional index >38.5) group (p < 0.001). In Cox regression analysis, Eastern Cooperative Oncology Group performance score (HR: 2.5), time to systemic treatment (HR: 1.7) and prognostic nutritional index (HR: 1.8) were associated with overall survival.

In patients with renal cell cancer, prognostic nutritional index is closely related to survival and has prognostic significance.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2019 Oct 25 [Epub ahead of print]

Hatime Arzu Yasar, Kadriye Bir Yucel, Cagatay Arslan, Gokhan Ucar, Serdar Karakaya, Burak Bilgin, Hakan Taban, Ahmet Kucukarda, Ismail Erturk, Mutlu Hızal, Birol Yıldız, Nuriye Yıldırım, Umut Demirci, Mehmet Ali Sendur, Gungor Utkan, Saadettin Kılıckap, Irfan Cicin, Nuri Karadurmus, Yüksel Ürün

Faculty of Medicine, Medical Oncology Department, Ankara University Ankara, Turkey., Faculty of Medicine, Internal Medicine Department, Ankara University, Ankara, Turkey., Faculty of Medicine, Department of Internal Medicine and Medical Oncology, Bahcesehir University, Istanbul, Turkey., Ankara Numune Education and Research Hospital, Medical Oncology Department, University of Health Sciences, Ankara, Turkey., Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Medical Oncology Department, University of Health Sciences, Ankara, Turkey., Faculty of Medicine, Medical Oncology Department, Ankara Yıldırım Beyazıt University, Ankara, Turkey., Faculty of Medicine, Medical Oncology Department, Hacettepe University, Ankara, Turkey., Faculty of Medicine, Department of Medical Oncology, Trakya University, Edirne, Turkey., Gülhane Education and Research Hospital, Medical Oncology Department, University of Health Sciences, Ankara, Turkey.

X